View Item 

Show simple item record

Concomitant use of isotretinoin and lasers with implications for future guidelines: An updated systematic review
dc.contributor.authorMirza, Fatima N.
dc.contributor.authorMirza, Humza N.
dc.contributor.authorKhatri, Khalil A.
dc.date.accessioned2021-01-05T18:48:17Z
dc.date.availableWITHHELD_11_MONTHS
dc.date.available2021-01-05T18:48:17Z
dc.date.issued2020-11
dc.identifier.citationMirza, Fatima N.; Mirza, Humza N.; Khatri, Khalil A. (2020). "Concomitant use of isotretinoin and lasers with implications for future guidelines: An updated systematic review." Dermatologic Therapy 33(6): n/a-n/a.
dc.identifier.issn1396-0296
dc.identifier.issn1529-8019
dc.identifier.urihttps://hdl.handle.net/2027.42/163929
dc.description.abstractIt is generally believed that intervention on skin while on isotretinoin or within 6 to 12 months after treatment can lead to prolonged healing and abnormal scarring. The objective of this systematic review is to evaluate the body of evidence on concomitant use of isotretinoin and lasers for adverse events as a consequence of treatment. A PRISMA‐compliant systematic review (Systematic Review Registration Number: CRD42017056492) of 12 electronic databases was conducted for the terms “laser” and “isotretinoin” or associated brand names from inception until June 2020. Subsequent reference search of studies meeting predefined inclusion criteria were conducted, and all articles were evaluated for bias and assigned levels of evidence to facilitate data synthesis. The search strategy produced 29 studies. Of 871 patients included in the studies of interest, 12 experienced transient adverse effects that resolved spontaneously, and only two presented with keloid formation, both from case reports. This systematic review suggests the risk associated with concomitant isotretinoin and laser use is small to absent. Further studies are needed, but these results suggest that current contraindications may be overly cautious.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othersystematic review
dc.subject.othersafe and effective
dc.subject.otherconcomitant treatment
dc.subject.otherisotretinoin
dc.subject.otherlasers
dc.titleConcomitant use of isotretinoin and lasers with implications for future guidelines: An updated systematic review
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDermatology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163929/1/dth14022.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/163929/2/dth14022_am.pdf
dc.identifier.doi10.1111/dth.14022
dc.identifier.sourceDermatologic Therapy
dc.identifier.citedreferenceXia J, Hu G, Hu D, Geng S, Zeng W. Concomitant use of 1,550‐nm nonablative fractional laser with low‐dose isotretinoin for the treatment of acne vulgaris in asian patients: a randomized split‐face controlled study. Dermatol Surg. 2018; 44 ( 9 ): 1201 ‐ 1208. https://doi.org/10.1097/DSS.0000000000001546.
dc.identifier.citedreferenceHan J et al. A case of cutaneous Rosai‐Dofman disease treated with isotretinoin and pulsed dye laser. J Dermatol. 2012; 39 ( 1 ): 108.
dc.identifier.citedreferenceJeong M et al. Early ablative carbon dioxide fractional laser for acne scars in asian patients undergoing oral isotretinoin. J Investig Dermatol. 2013; 133 ( 1 ): S181.
dc.identifier.citedreferencePark HC, Kim EJ, Kim JE, Ro YS, Ko JY. Treatment of multiple eccrine hidrocystomas with isotretinoin followed by carbon dioxide laser. J Dermatol. 2013; 40: 414 ‐ 415. https://doi.org/10.1111/1346-8138.12059.
dc.identifier.citedreferenceNoh S, Shin JU, Jung JY, Lee JH. A case of sebaceous hyperplasia maintained on low‐dose isotretinoin after carbon dioxide laser treatment. Int J Dermatol. 2014; 53: e151 ‐ e153. https://doi.org/10.1111/j.1365-4632.2012.05823.x.
dc.identifier.citedreferenceYoon JH, Park EJ, Kwon IH, et al. Concomitant use of an infrared fractional laser with low‐dose isotretinoin for the treatment of acne and acne scars. J Dermatol Treat. 2014; 25 ( 2 ): 142 ‐ 146. https://doi.org/10.3109/09546634.2013.768758.
dc.identifier.citedreferenceChandrashekar BS, Varsha DV, Vasanth V, Jagadish P, Madura C, Rajashekar ML. Safety of performing invasive acne scar treatment and laser hair removal in patients on oral isotretinoin: a retrospective study of 110 patients. Int J Dermatol. 2014; 53 ( 10 ): 1281 ‐ 1285. https://doi.org/10.1111/ijd.12544.
dc.identifier.citedreferenceKim HW, Chang SE, Kim JE, Ko JY, Ro YS. The safe delivery of fractional ablative carbon dioxide laser treatment for acne scars in Asian patients receiving Oral isotretinoin. Dermatol Surg. 2014; 40 ( 12 ): 1361 ‐ 1366. https://doi.org/10.1097/DSS.0000000000000185.
dc.identifier.citedreferenceKhatri KA, Iqbal N, Bhawan J. Laser skin resurfacing during isotretinoin therapy. Dermatol Surg. 2015; 41 ( 6 ): 758 ‐ 759. https://doi.org/10.1097/DSS.0000000000000353.
dc.identifier.citedreferenceMahadevappa OH et al. Surgical outcome in patients taking concomitant or recent intake of oral isotretinoin: a multicentric study‐ISO‐AIMS study. J Cutan Aesthet Surg. 2016; 9 ( 2 ): 106 ‐ 112. https://doi.org/10.4103/0974-2077.184054.
dc.identifier.citedreferenceSaluja SS et al. Safety of non‐ablative fractional laser for acne scars within 1 month after treatment with oral isotretinoin: a randomized split‐face controlled trial. Lasers Surg Med. 2017; 49 ( 10 ): 886 ‐ 890. https://doi.org/10.1002/lsm.22711.
dc.identifier.citedreferencePestoni Porvén C, Vieira dos Santos V, del Pozo Losada J. Fractional carbon dioxide (CO2) laser combined with topical tretinoin for the treatment of different forms of cystic acne. J Cosmet Laser Ther. 2017; 19 ( 8 ): 465 ‐ 468. https://doi.org/10.1080/14764172.2017.1349323.
dc.identifier.citedreferenceDemirkan S. Treatment of multiple eccrine hidrocystoma with oral isotretinoin following erbium‐yttrium aluminum garnet laser. J Cosmet Laser Ther. 2019; 21 ( 1 ): 11 ‐ 13. https://doi.org/10.1080/14764172.2018.1427873.
dc.identifier.citedreferenceGold M et al. Treatment of moderate to severe acne and scars with a 650‐microsecond 1064‐nm laser and isotretinoin. J Drugs Dermatol. 2020; 19 ( 6 ): 19. https://doi.org/10.36849/JDD.2020.5108.
dc.identifier.citedreferenceKwon HH et al. Combined treatment of recalcitrant papulopustular rosacea involving pulsed dye laser and fractional microneedling radiofrequency with low‐dose isotretinoin. J Cosmet Dermatol. 2020; 19 ( 1 ): 105 ‐ 111. https://doi.org/10.1111/jocd.12982.
dc.identifier.citedreferenceKim J et al. Safety of combined fractional microneedle radiofrequency and CO2 as an early intervention for inflammatory acne and scarring treated with concomitant isotretinoin. Dermatol Surg. 2020; 1. https://doi.org/10.1097/dss.0000000000002364. [Epub ahead of print].
dc.identifier.citedreferenceMa D, Li Q, Jin D, Sun M, Nie X. A case of lupus miliaris disseminatus faciei that was successfully treated with 595 nm pulsed‐dye laser combined with drugs. Dermatol Ther. 2020; 33: e13373. https://doi.org/10.1111/dth.13373.
dc.identifier.citedreferenceDogan G. Possible isotretinoin‐induced keloids in a patient with Behcet’s disease. Clin Exp Dermatol. 2006; 31 ( 4 ): 535 ‐ 537. https://doi.org/10.1111/j.1365-2230.2006.02140.x.
dc.identifier.citedreferenceGinarte M, Peteiro C, Toribio J. Keloid formation induced by isotretinoin therapy. Int J Dermatol. 1999; 38 ( 3 ): 228 ‐ 229. http://www.ncbi.nlm.nih.gov/pubmed/10208624 Accessed January 31, 2017.
dc.identifier.citedreferenceRobinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews. Arch Dermatol. 2008; 144 ( 1 ): 97 ‐ 99. https://doi.org/10.1001/archdermatol.2007.28.
dc.identifier.citedreferenceAlexiades‐Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008; 58: 719 ‐ 737. https://doi.org/10.1016/j.jaad.2008.01.003.
dc.identifier.citedreferencePozner JN, DiBernardo BE. Laser resurfacing: full field and fractional. Clin Plast Surg. 2016; 43: 515 ‐ 525. https://doi.org/10.1016/j.cps.2016.03.010.
dc.identifier.citedreferenceTolkachjov SN, Sahoo A, Patel NG, Lohse CM, Murray JA, Tollefson MM. Surgical outcomes of patients on isotretinoin in the perioperative period: a single‐center, retrospective analysis. J Am Acad Dermatol. 2017; 77 ( 1 ): 159 ‐ 161. https://doi.org/10.1016/j.jaad.2017.03.019.
dc.identifier.citedreferenceBickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004. J Am Acad Dermatol. 2006; 55 ( 3 ): 490 ‐ 500. https://doi.org/10.1016/j.jaad.2006.05.048.
dc.identifier.citedreferenceFitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5‐FU. Dermatol Surg. 1999; 25 ( 3 ): 224 ‐ 232. http://www.ncbi.nlm.nih.gov/pubmed/10193972 Accessed May 20, 2017.
dc.identifier.citedreferenceLupton JR, Alster TS. Laser scar revision. Dermatol Clin. 2002; 20 ( 1 ): 55 ‐ 65. https://doi.org/10.1016/S0733-8635(03)00045-7.
dc.identifier.citedreferenceMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med. 2009; 6 ( 7 ): e1000097. https://doi.org/10.1371/journal.pmed.1000097.
dc.identifier.citedreferenceHowick, J. et al. ( 2011 ) The 2011 Oxford CEBM Levels of Evidence. http://www.cebm.net/index.aspx?o=5653 Accessed January 31, 2017.
dc.identifier.citedreferenceSterne JA, Harnán MA, Reeves BC, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ. 2016; 355: i4919. http://www.ncbi.nlm.nih.gov/pubmed/27733354 Accessed February 2, 2017.
dc.identifier.citedreferenceZachariae H. Delayed wound healing and keloid formation following argon laser treatment or dermabrasion during isotretinoin treatment. Br J Dermatol. 1988; 118 ( 5 ): 703 ‐ 706. http://www.ncbi.nlm.nih.gov/pubmed/2969261 Accessed February 1, 2017.
dc.identifier.citedreferenceBernestein LJ, Geronemus RG. Keloid formation with the 585‐nm pulsed dye laser during isotretinoin treatment. Arch Dermatol. 1997; 133 ( 1 ): 111 ‐ 112. http://www.ncbi.nlm.nih.gov/pubmed/9006390 Accessed February 1, 2017.
dc.identifier.citedreferenceKhatri KA. Diode laser hair removal in patients undergoing isotretinoin therapy. Dermatol Surg. 2004; 30 ( 9 ): 1205 ‐ 1207. https://doi.org/10.1111/j.1524-4725.2004.30373.x.
dc.identifier.citedreferenceCassano N, Arpaia N, Vena GA. Diode laser hair removal and isotretinoin therapy. Dermatol Surg. 2005; 31 ( 3 ): 380 ‐ 381. http://www.ncbi.nlm.nih.gov/pubmed/15841649 Accessed February 1, 2017.
dc.identifier.citedreferenceMoradi A et al. Co‐administration of isotretinoin and laser treatments. Lasers Surg Med. 2005; 36 ( 17 ): 39.
dc.identifier.citedreferenceKhatri K, Garcia V. Letter: light‐assisted hair removal in patients undergoing isotretinoin therapy. Dermatol Surg. 2006; 32 ( 6 ): 875 ‐ 877. https://doi.org/10.1111/j.1524-4725.2006.32182.x.
dc.identifier.citedreferenceKhatri KA. The safety of long‐pulsed Nd:YAG laser hair removal in skin types III–V patients during concomitant isotretinoin therapy. J Cosmet Laser Ther. 2009; 11 ( 1 ): 56 ‐ 60. https://doi.org/10.1080/14764170802612984.
dc.identifier.citedreferenceMoradi A et al. Co‐administration of Nlite and Er:yag laser with isotretinoin. Lasers Surg Med. 2009; 41: 34 ‐ 35.
dc.identifier.citedreferenceHann S‐K et al. Concomitant use of infrared fractional laser with low dose isotretinoin. Lasers Surg Med. 2010; 25 ( 22 ): 22.
dc.identifier.citedreferenceAlissa A. Concomitant use of laser and isotretinoin, how safe? Lasers Surg Med. 2011; 43 ( 23 ): 943.
dc.identifier.citedreferenceLeal H, Cantu P. Fractionated erbium laser during oral isotretinoin treatment. J Am Acad Dermatol. 2011; 64 ( 2, 1 ): AB18.
dc.identifier.citedreferencePatwardhan M et al. Isotretinoin and lasers: can they be used at the same time? J Am Acad Dermatol. 2012; 66 ( 4 ): AB28. https://doi.org/10.1016/j.jaad.2011.11.123.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
dth14022.pdf
Size:
1.204MB
Format:
PDF
View/Open
Name:
dth14022_am.pdf
Size:
486.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.